Fundraising Fox
/Companies
Sign in

Montis Biosciences

Leuven, BE · 6 known investors

Find your way into Montis Biosciences

Sign up to find every way you can get introduced to Montis Biosciences

  • Your email: who you already know at Montis Biosciences, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Montis Biosciences team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Montis Biosciences is a biotechnology company developing anti-C1q antibodies that target both the complement and myeloid axes to treat neuroinflammatory, autoimmune, neurodegenerative and ophthalmic diseases, with a lead program in Guillain-Barré syndrome. It also has a second program inhibiting CD93 for lung squamous cell carcinoma.

BiotechHealthtech

Founders & leadership

FG
Federico GrossiClinical Advisor & Acting CMO

Investors · 6

Droia Ventures✓ confirmed by Montis BiosciencesLuxembourg · $540K

How we know: the company's own site · biospace.com · droiaventures.com · Not right? Tell us

Pfizer Ventures✓ confirmed by Montis Biosciences

How we know: the company's own site · biospace.com · Not right? Tell us

VIB✓ confirmed by Montis BiosciencesGhent

How we know: the company's own site · Not right? Tell us

Pfizer Venture Investmentslisted by Pfizer Venture Investments$5M – $20M

How we know: the VCSheet dataset · Not right? Tell us

Also in the syndicate · 1

Polaris Partners

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Montis Biosciences Awarded VLAIO Grant to Expand its Pipeline of Novel Immune-Oncology Therapeutics – Droia Ventures – Investing in Impactdroiaventures.com · Jun 2021Montis Biosciences launched with €8,4 million seed financing and a novel approach to immuno-oncology - BioSpacebiospace.com · Feb 2020

Frequently asked questions

What does Montis Biosciences do?
Montis Biosciences is a biotechnology company developing anti-C1q antibodies that target both the complement and myeloid axes to treat neuroinflammatory, autoimmune, neurodegenerative and ophthalmic diseases, with a lead program in Guillain-Barré syndrome. It also has a second program inhibiting CD93 for lung squamous cell carcinoma.
Who are Montis Biosciences's investors?
Montis Biosciences's investors include ALSA Ventures, Droia Ventures, Pfizer Ventures, VIB, Pfizer Venture Investments.
Where is Montis Biosciences headquartered?
Montis Biosciences is headquartered in Leuven, BE.